NordiStrazol 1mg/tab 50 Tabletten by Nordi Pharma

Usage

1. CALCULATE START DATE: Using your longest ester's half-life, multiply by five to estimate androgen clearance time — this is your earliest valid anastrozole initiation window after the final injection.
2. CONFIRM WITH BLOODWORK: Draw serum total testosterone and estradiol (LC-MS/MS preferred) on days 10–12 post-injection. Only initiate NordiStrazol if testosterone is clearly declining and estradiol is trending upward.
3. SELECT YOUR ENTRY DOSE: Choose 0.5 mg (half tablet) for a moderate estradiol rise; use the full 1 mg tablet if estradiol is acutely elevated at bloodwork. Use a clean pill cutter for consistent halves.
4. TAKE AT THE SAME TIME DAILY: Anastrozole reaches stable plasma levels within 7 days of consistent daily dosing. Morning administration with water is conventional; food does not meaningfully affect absorption.
5. MONITOR AT WEEK 2: Recheck estradiol mid-protocol. Adjust dose up or down based on results — the 1 mg tablet format supports dose flexibility without requiring different-strength products.
6. TRANSITION TO CLOSE: As LH, FSH, and total testosterone return toward reference range on bloodwork, taper NordiStrazol frequency before full discontinuation. Do not stop abruptly at peak dose — step down over 7–10 days.

Warnings

Frequently asked questions

When exactly should I start taking anastrozole after my last testosterone injection?

Start NordiStrazol approximately 10–14 days after your final long-ester injection — the point at which circulating androgen levels are declining rapidly and estradiol begins its rebound. This timing aligns CYP19A1 inhibition with actual physiological need. Calculating from the ester's half-life (e.g. 4.5 days for Enanthate) and applying a five-half-life clearance window gives the most accurate start date.

What happens to estradiol if you start PCT anastrozole too late?

Delaying anastrozole beyond the washout window allows residual androgens to aromatise unopposed, producing an estradiol spike. Elevated estradiol suppresses hypothalamic GnRH pulsatility and weakens the pituitary LH response — the opposite of what recovery requires. Even a one-week delay in introducing CYP19A1 inhibition can compress the effective recovery window and extend total PCT duration.

Which blood test values tell you the right time to begin anastrozole in PCT?

Total testosterone falling below 150–200 ng/dL combined with estradiol rising above 30–40 pg/mL (measured by LC-MS/MS for accuracy) signals that aromatase inhibition is pharmacologically justified. These markers confirm androgen suppression is real and that the conversion pathway is active. Testing on day 10–12 post-injection provides the data needed to confirm or adjust the planned anastrozole start date.

Can NordiStrazol 1mg tablets be split to fine-tune the starting dose?

Yes — the 1 mg tablet format supports halving for a 0.5 mg entry dose, which is appropriate when estradiol is moderately elevated at PCT initiation rather than acutely high. Splitting allows a graduated approach to CYP19A1 inhibition, reducing the risk of overcorrection into low-estradiol symptoms during the sensitive early PCT window. Tablet integrity supports clean splitting with a standard pill cutter.

How many NordiStrazol tablets are typically needed to cover the full PCT timing window?

A standard timed protocol using 0.5–1 mg daily over a 4–6 week aromatase-inhibition phase consumes 14–42 tablets depending on dose and duration. The 50-tablet pack is sized to cover this range in a single supply, including a short overlap with the SERM phase if sequential scheduling is used. No mid-protocol resupply is required for the majority of timing-structured PCT plans. (2) angle_used

Manufacturer

Nordi Pharma's approach to API sourcing for NordiStrazol begins at the raw material level — a stage that the company treats as analytically distinct from, and equally critical as, the finished-product release process. Anastrozole API supplied to Nordi Pharma's production facility undergoes identity verification and purity screening against documented specification limits before any tablet manufacturing step is authorised to proceed. This upstream gating means that only API batches passing incoming quality criteria enter the granulation and compression sequence, establishing a traceable chain of material accountability from supplier certificate of analysis through to the finished blister. The finished tablet is subsequently subjected to independent HPLC potency testing against a certified anastrozole reference standard, confirming that the declared 1 mg active content is present within specification tolerance. Nordi Pharma structures these two checkpoints — incoming API and finished product — as separate, non-overlapping analytical events, so that a passing raw-material result cannot substitute for or mask a finished-product verification failure. GMP-aligned manufacturing conditions govern the production environment throughout.